Mr. Speaker, as I said on April 27, we have to follow a process, whereby the Department of Health along with its researchers and scientists must ensure that the medication they are about to approve will serve its purpose.
The 22-month delay may have been due to the great number of drugs we have to examine. As you know, we have a deficit and debt problem. We receive a lot of submissions for new drugs. As the list gets longer and longer, so do the delays.
There is no reason why the medication should not be approved shortly.